Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

1.

Statins and HIV medication: a view from primary care.

Singh S, Paul EJ, Kozlowska R.

Sex Transm Infect. 2011 Dec;87(7):656. doi: 10.1136/sextrans-2011-050273. Epub 2011 Oct 6. No abstract available.

PMID:
21980119
[PubMed - indexed for MEDLINE]
2.

Gynecomastia, lipodystrophy syndrome, and dyslipidemia occurring or worsening during antiretroviral regimens other than protease inhibitor-based ones.

Manfredi R, Calza L, Chiodo F.

J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):99-102. No abstract available.

PMID:
14707802
[PubMed - indexed for MEDLINE]
3.

Abstracts of the 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. London, United Kingdom. November 6-8, 2008.

[No authors listed]

Antivir Ther. 2008;13(8):A3-92. No abstract available.

PMID:
19350735
[PubMed - indexed for MEDLINE]
4.

Statins in HIV-associated lipodystrophy and metabolic syndrome: is there a missing link?

Gharakhanian S, Boccara F, Capeau J.

AIDS. 2006 Apr 24;20(7):1061-3. No abstract available.

PMID:
16603860
[PubMed - indexed for MEDLINE]
5.

Sweetening the toxic cocktail. Managing the side effects of HIV medications.

Doerfler RE.

Adv Nurse Pract. 2002 May;10(5):52-4, 57-8, 103. Review. No abstract available.

PMID:
12420531
[PubMed - indexed for MEDLINE]
6.

Lipid-lowering effect of tenofovir in HIV-infected patients.

Fabbiani M, Bracciale L, Doino M, Sidella L, Farina S, Di Cristo V, Cauda R, De Luca A, Di Giambenedetto S.

J Antimicrob Chemother. 2011 Mar;66(3):682-3. doi: 10.1093/jac/dkq464. Epub 2010 Dec 5. No abstract available.

PMID:
21131692
[PubMed - indexed for MEDLINE]
Free Article
7.

Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.

Negredo E, Paredes R, Bonjoch A, Tuldrà A, Fumaz CR, Gel S, Garcés B, Johnston S, Arnó A, Balagué M, Jou A, Tural C, Sirera G, Romeu J, Cruz L, Francia E, Domingo P, Arrizabalaga J, Ruiz I, Arribas JR, Ruiz L, Clotet B.

Antivir Ther. 1999;4 Suppl 3:23-8.

PMID:
16021868
[PubMed - indexed for MEDLINE]
8.

[Utility of atazanavir in special populations].

Antela López A.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:49-54. doi: 10.1016/S0213-005X(08)76621-7. Review. Spanish.

PMID:
20116618
[PubMed - indexed for MEDLINE]
9.

Hepatitis C virus in patients with HIV infection and lipodystrophy.

Rodriguez-Guardado A, Maradona JA, Asensi V, Cartón JA, Casado L.

J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):348-9. No abstract available.

PMID:
12626899
[PubMed - indexed for MEDLINE]
10.

Evaluation of the risk factors associated with lipodystrophy development in a cohort of HIV-positive patients.

Seminari E, Tinelli C, Minoli L, Sacchi P, Filice G, Zocchetti C, Meneghetti G, Bruno R, Maserati R.

Antivir Ther. 2002 Sep;7(3):175-80.

PMID:
12487384
[PubMed - indexed for MEDLINE]
11.

HIV-associated asymmetric lipodystrophy syndrome.

Quiros-Roldan E, Moretti F, Torti C, Casari S, Prestini K, Carosi G.

Rev Clin Esp. 2004 Mar;204(3):177. No abstract available.

PMID:
15025990
[PubMed - indexed for MEDLINE]
12.

Bullets, balance, or both: medicalisation in HIV treatment.

Patton C.

Lancet. 2007 Feb 24;369(9562):706-7. No abstract available.

PMID:
17321320
[PubMed - indexed for MEDLINE]
13.

Assessment of ultrasound for use in detecting lipoatrophy in HIV-infected patients taking combination antiretroviral therapy.

Viskovic K, Richman I, Klasnic K, Hernandez A, Krolo I, Rutherford GW, Romih V, Begovac J.

AIDS Patient Care STDS. 2009 Feb;23(2):79-84. doi: 10.1089/apc.2008.0118.

PMID:
19133752
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

More on abacavir-induced neuropsychiatric reactions.

Foster R, Taylor C, Everall IP.

AIDS. 2004 Dec 3;18(18):2449. No abstract available.

PMID:
15622330
[PubMed - indexed for MEDLINE]
15.

[Indinavir-associated lipodystrophy].

Krautheim A.

Praxis (Bern 1994). 1999 Feb 11;88(7):285-7. German. No abstract available.

PMID:
10097649
[PubMed - indexed for MEDLINE]
16.

Targets of metabolic toxicity of HIV antiretroviral drugs: the multiple roads to lipodystrophy and metabolic syndrome.

Domingo P, Villarroya F.

Curr Pharm Des. 2010 Oct;16(30):3337-8. No abstract available.

PMID:
20687885
[PubMed - indexed for MEDLINE]
17.

Prevalence of possible drug-drug interactions between antiretroviral agents in different age groups in a section of the private health care sector setting in South Africa.

Katende-Kyenda NL, Lubbe MS, Serfontein JH, Truter I.

J Clin Pharm Ther. 2008 Aug;33(4):393-400. doi: 10.1111/j.1365-2710.2008.00930.x.

PMID:
18613857
[PubMed - indexed for MEDLINE]
18.

Outcome assessment of decentralization of antiretroviral therapy provision in a rural district of Malawi using an integrated primary care model.

Chan AK, Mateyu G, Jahn A, Schouten E, Arora P, Mlotha W, Kambanji M, van Lettow M.

Trop Med Int Health. 2010 Jun;15 Suppl 1:90-7. doi: 10.1111/j.1365-3156.2010.02503.x.

PMID:
20586966
[PubMed - indexed for MEDLINE]
Free Article
19.

Effectiveness of collaborative care for depression in human immunodeficiency virus clinics.

Pyne JM, Fortney JC, Curran GM, Tripathi S, Atkinson JH, Kilbourne AM, Hagedorn HJ, Rimland D, Rodriguez-Barradas MC, Monson T, Bottonari KA, Asch SM, Gifford AL.

Arch Intern Med. 2011 Jan 10;171(1):23-31. doi: 10.1001/archinternmed.2010.395.

PMID:
21220657
[PubMed - indexed for MEDLINE]
20.

Abstracts from the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, California, USA. September 22-25, 2002.

[No authors listed]

Antivir Ther. 2002 Sep;7(3):L1-66. No abstract available.

PMID:
14712811
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk